Chemomab Therapeutics
CMMBChemomab Therapeutics Ltd. (NASDAQ: CMMB) is a clinical-stage biotechnology company based in Israel. The company's primary business focus is the development of monoclonal antibody therapies designed to treat fibrotic and inflammatory diseases with high unmet medical need. Its lead candidate, CM-101, is a humanized monoclonal antibody that specifically targets CCL24, a soluble protein implicated in driving fibrosis and inflammation across multiple organ systems. The company's research and development pipeline is concentrated on systemic sclerosis, primary sclerosing cholangitis, and metabolic dysfunction-associated steatohepatitis. Chemomab has advanced CM-101 into Phase 2 clinical trials for these indications to evaluate its safety and efficacy. The therapeutic approach is based on the hypothesis that neutralizing CCL24 may directly address underlying pathological processes common to these conditions. As a publicly traded entity, Chemomab Therapeutics operates within the biotechnology and immunology sectors. Its strategic efforts are directed toward generating clinical data to validate the role of the CCL24 pathway and the potential of CM-101 as a targeted treatment. The company's activities are funded through public market financing and collaborations, supporting its clinical trial programs and research operations.
CMMB · Stock Price
Historical price data
About
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) is a clinical-stage biotechnology company based in Israel. The company's primary business focus is the development of monoclonal antibody therapies designed to treat fibrotic and inflammatory diseases with high unmet medical need. Its lead candidate, CM-101, is a humanized monoclonal antibody that specifically targets CCL24, a soluble protein implicated in driving fibrosis and inflammation across multiple organ systems. The company's research and development pipeline is concentrated on systemic sclerosis, primary sclerosing cholangitis, and metabolic dysfunction-associated steatohepatitis. Chemomab has advanced CM-101 into Phase 2 clinical trials for these indications to evaluate its safety and efficacy. The therapeutic approach is based on the hypothesis that neutralizing CCL24 may directly address underlying pathological processes common to these conditions. As a publicly traded entity, Chemomab Therapeutics operates within the biotechnology and immunology sectors. Its strategic efforts are directed toward generating clinical data to validate the role of the CCL24 pathway and the potential of CM-101 as a targeted treatment. The company's activities are funded through public market financing and collaborations, supporting its clinical trial programs and research operations.